Actively Recruiting
Randomized, Double-Blind Study to Evaluate Safety and Effects of SA030 Injection in Overweight or Obese Adults
Led by Suzhou Siran Biotechnology Co.,Ltd. · Updated on 2026-10-23
40
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying SA030 injection in people who are overweight or obese to understand its safety, how well it is tolerated, and how the body processes a single dose. This is the first time SA030 is being given to humans, and the study aims to gather important information about its effects in this population. The research is motivated by the increasing number of overweight and obese individuals worldwide over recent decades. Participants will receive either a single dose of SA030 at one of five dose levels or a matching placebo. The study follows a randomized, double-blind, placebo-controlled design where participants are assigned sequentially to these groups. This phase I study focuses on assessing the initial safety, tolerability, and pharmacokinetics of SA030 in this group. During the study, participants will be monitored for adverse events and laboratory abnormalities for about six months. Blood samples will be taken at multiple timepoints up to five days post-dose to measure drug levels and related pharmacokinetic parameters. Researchers will also track changes in weight, body measurements, body fat content, and specific biomarkers over 24 weeks. Electrocardiograms and other health assessments will be performed to ensure safety and evaluate effects throughout the study period.
CONDITIONS
Brief Title
A Study of SA030 Injection in Overweight or Obese Participants
Research Team
F
Feifei Zhao
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here